Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-10 (2017) Cardiovascular diabetology 16(1), 70 (2017). doi:10.1186/s12933-017-0552-4 Müller-Wieland, D, Leiter, L A, Cariou, B, Letierce, A, Colhoun, H M, Del Prato, S, Henry, R R, Tinahones, F J, Aurand, L, Maroni, J, Ray, K K & Bujas-Bobanovic, M 2017, ' Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial : lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk ', Cardiovascular diabetology, vol. 16, no. 1, pp. 70 . https://doi.org/10.1186/s12933-017-0552-4 Cardiovascular Diabetology